Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 7 Lymphoma 4 Unspecified Adult Solid Tumor, Protocol Specific 3 Recurrence 2 Neuroblastoma 2 Lymphoma, Non-Hodgkin 2 Solid Tumors 1 Melanoma 1 Lymphoma, Large-Cell, Anaplastic 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hodgkin Disease 1 Hematologic Neoplasms 1 Hematologic Diseases 1 Carcinoma 1 Advanced Cancer 1 Adult Solid Neoplasm 1

Interventions

Nivolumab 8 Paclitaxel 6 Sirolimus 5 Bevacizumab 5 temsirolimus 4 Pemetrexed 4 Ipilimumab 4 Docetaxel 4 Carboplatin 4 ARRY-334543 4 Gemcitabine 3 Erlotinib Hydrochloride 3 olaparib 2 linrodostat 2 apatinib 2 anlotinib 2 abemaciclib 2 Vorinostat 2 Sunitinib 2 Magnetic Resonance Spectroscopy 2 Irinotecan 2 Everolimus 2 Doxorubicin 2 Dasatinib 2 Chlorogenic Acid 2 Cetuximab 2 6-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline 2 vorolanib 1 vistusertib 1 trametinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Advanced Cancer × Ketoconazole × Clear all

NCT00708591 2014-01-17

Study of Rapamycin Plus Ketoconazole in Advanced Cancers

University of Chicago

Phase 1 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡